Business Context and Reporting Period
This Form 8-K is a current report filed by Relmada Therapeutics, Inc. on August 17, 2018. The filing addresses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance regarding the audit firm.
Material Changes
- Accountant Change: The Company accepted the resignation of GBH CPAs, PC and engaged Marcum LLP as its new independent registered public accounting firm.
- Reason for Change: The change resulted from GBH CPAs, PC combining its practice with Marcum LLP, effective July 1, 2018.
- Approval: The engagement of Marcum LLP was approved by the Company's Audit Committee.
Guidance, Outlook, and Disclosures
The filing includes standard disclosures regarding the relationship with the former accountant (GBH CPAs, PC) for the fiscal years ended June 30, 2017 and 2016, and through August 17, 2018:
- Audit Opinions: GBH's reports did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
- Disagreements: There were no disagreements with GBH on accounting principles, practices, or auditing scope/procedures.
- Consultations: The Company did not consult with Marcum LLP regarding accounting applications, potential audit opinions, or matters of disagreement prior to the engagement.
Investor Verification Checklist
- Verify the transition timeline between GBH CPAs, PC and Marcum LLP to ensure no gap in audit coverage.
- Review the letter from GBH CPAs, PC (Exhibit 16.1) to confirm their agreement with the Company's disclosures.
- Monitor future filings for the first financial statements audited by Marcum LLP to assess any changes in accounting treatment or audit findings.